Stock comparison
IDEXX Laboratories
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$43.63B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.27B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 77B | LMAT |
| Benjamin Graham | 80A | 89A | LMAT |
| Philip Fisher | 75B | 81C | LMAT |
| Peter Lynch | 71B | 67B | IDXX |
| Joel Greenblatt | 83C | 56D | IDXX |
| Charlie Munger | 87A | 68D | IDXX |
| Terry Smith | 84A | 69D | IDXX |
Side-by-side metrics
| Metric | IDXX | LMAT |
|---|---|---|
| Market cap | $43.63B | $2.27B |
| P/E (TTM) | 39.0x | 37.1x |
| EV/EBIT | 31.6x | 36.6x |
| ROIC (TTM) | 40.66% | 9.43% |
| Gross margin | 62.05% | 72.39% |
| Net margin | 24.63% | 24.35% |
| Revenue CAGR 5y | 7.56% | 12.75% |
| EPS CAGR 5y | 10.79% | 19.04% |
| Debt / Equity | 0.7x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$43.63Bvs $2.27B+95%
- ROIC (TTM)40.66%vs 9.43%+77%
- EV/EBIT31.6xvs 36.6x+14%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- EPS CAGR 5y19.04%vs 10.79%+43%
- Revenue CAGR 5y12.75%vs 7.56%+41%
- Debt / Equity0.5xvs 0.7x+33%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.